Fulgent Genetics COO has 4,361 shares withheld

Q: How many FLGT shares did Jian Xie have withheld, and at what price?

Jian Xie, Fulgent Genetics' President and COO, had 4,361 shares withheld at $20.22 per share on October 26, 2026. His direct holdings following the transaction were 355,563 shares.

Q: What does Jian Xie's FLGT filing say about the trust shares?

The Hsieh Family Dynasty Trust held 220,816 shares. Xie serves on the Trust's investment committee and disclaims any beneficial interest except with respect to any pecuniary interest therein.

Q: Why were shares withheld from Jian Xie?

The 4,361 shares were withheld to satisfy tax withholding obligations arising upon vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger dated November 7, 2022.

The President and COO's transaction was tied to tax withholding on restricted stock units, with 355,563 shares held directly afterward.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Fulgent Genetics, Inc. President and COO Jian Xie had 4,361 shares withheld on October 26, 2026, to satisfy tax withholding obligations upon vesting of certain restricted stock units; the reported price was $20.22 per share. His direct holdings after the transaction were 355,563 shares. Separately, 220,816 shares were held by The Hsieh Family Dynasty Trust.

Insider Trade Summary

Tax Withholding: 4,361 shares

Tax Withholding 2 txns

Insider Xie Jian

Role President and COO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock ^F1	4,361	$20.22	$88K
holding	Common Stock ^F2	--	--	--

Holdings After Transaction: Common Stock — 355,563 shares (Direct); Common Stock — 220,816 shares (Indirect, By Trust)

Footnotes (2)

F1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.
F2. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

Key Figures

Shares withheld: 4,361 shares Reported price per share: $20.22 per share Direct shares following transaction: 355,563 shares +1 more

4 metrics

Shares withheld 4,361 shares October 26, 2026, for tax withholding upon restricted stock unit vesting

Reported price per share $20.22 per share Shares withheld on October 26, 2026

Direct shares following transaction 355,563 shares October 26, 2026

Trust-held shares 220,816 shares Held by The Hsieh Family Dynasty Trust on October 26, 2026

Key Terms

restricted stock units, tax withholding obligations, pecuniary interest

3 terms

restricted stock units financial

"vesting of certain restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"satisfy the tax withholding obligations"

pecuniary interest technical

"except with respect to any pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FLGT shares did Jian Xie have withheld, and at what price?

Jian Xie, Fulgent Genetics' President and COO, had 4,361 shares withheld at $20.22 per share on October 26, 2026. His direct holdings following the transaction were 355,563 shares.

What does Jian Xie's FLGT filing say about the trust shares?

The Hsieh Family Dynasty Trust held 220,816 shares. Xie serves on the Trust's investment committee and disclaims any beneficial interest except with respect to any pecuniary interest therein.

Why were shares withheld from Jian Xie?

The 4,361 shares were withheld to satisfy tax withholding obligations arising upon vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger dated November 7, 2022.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/28/2026 - 04:19 PM EDT Accepted by SEC EDGAR 10/28/2026 - 04:18 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xie Jian

(Last)

(First)

(Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE

CALIFORNIA

91731

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/26/2026		F		4,361⁽¹⁾	D	$20.22	355,563	D
Common Stock								220,816	I	By Trust⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

2. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

	/s/ Paul Kim as Attorney-in-Fact	10/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR